Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Diacylglycerol kinase zeta pseudogene 1 (DGKZP1) is classified as a pseudogene and does not encode for a functional protein[1][2][8]. Pseudogenes are segments of DNA that resemble functional genes but have lost their protein-coding potential or are otherwise non-functional due to mutations or evolutionary changes. There is no experimental evidence linking DGKZP1 to biological functions, disease roles, or drug interactions. Consequently, DGKZP1 is not considered a therapeutic target, and no mechanism of action, biomarker, or safety concern information is available for this sequence[1][2][8]. This entry is sometimes confused with "Diacylglycerol kinase zeta" (abbreviation: DGKZ), which is an active enzyme involved in signal transduction, but DGKZP1 itself is only a pseudogene and not a functional molecular target[4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Diacylglycerol kinase zeta pseudogene 1 (DGKZP1).